Knowledge, Attitudes, and Experiences of HIV Pre-Exposure Prophylaxis (PrEP) Trial Participants in Botswana

作     者：Lauren Toledo Eleanor McLellan-Lemal Faith L. Henderson Poloko M. Kebaabetswe 

作者机构：ICF International Atlanta USA Division of HIV/AIDS Prevention National Center for HIV Viral Hepatitis STD and TB Prevention Centers for Disease Control and Prevention (CDC) Atlanta USA HIV Prevention Research Unit CDC Botswana Gaborone Botswana Faculty of Medicine University of Botswana Gaborone Botswana 

出 版 物：《World Journal of AIDS》 (艾滋病（英文）)

年 卷 期：2015年第5卷第1期

页      面：10-20页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Pre-Exposure Prophylaxis HIV/AIDS Botswana Qualitative Research 

摘      要：Recent clinical trials have shown that a daily dose of oral TDF/FTC pre-exposure prophylaxis (PrEP) is effective in reducing human immunodeficiency (HIV) risk. Understanding trial participants’ perspectives about retention and PrEP adherence is critical to inform future PrEP trials and the scale-up and implementation of PrEP programs. We analyzed 53 in-depth interviews conducted in April 2010 with participants in the TDF2 study, a Phase 3, randomized, double-blind, place-bo-controlled clinical trial of daily oral TDF/FTC with heterosexual men and women in Francistown and Gaborone, Botswana. We examined participants’ knowledge, attitudes, and experiences of the trial, identified facilitators and barriers to enrollment and retention, and compared participant responses by study site, sex, and study drug adherence. Our findings point to several factors to consider for participant retention and adherence in PrEP trials and programs, including conducting pre-enrollment education and myth reduction counseling, providing accurate estimates of participant obligations and side effect symptoms, ensuring participant understanding of the effects of non-adherence, gauging personal commitment and interest in study outcomes, and developing a strong external social support network for participants.